Oruka Therapeutics (ORKA) Current Deferred Revenue (2010 - 2013)

Oruka Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $3000.0 for Q2 2013.

• On a quarterly basis, Current Deferred Revenue fell 90.91% year-over-year to $3000.0 in Q2 2013; TTM through Jun 2013 was $3000.0, a 90.91% decrease from a year earlier, with the FY2012 full-year figure at $16000.0, down 51.52% from the prior year.
• Current Deferred Revenue retreated to $3000.0 in Q2 2013 per ORKA's latest filing, from $8000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $121000.0 in Q4 2010 and bottomed at $3000.0 in Q2 2013.
• The 4-year median for Current Deferred Revenue is $32500.0 (2011), against an average of $33600.0.
• Across the five-year window, Current Deferred Revenue changed 0.0% in 2012 and plunged 90.91% in 2013, its largest moves.
• Year by year, Current Deferred Revenue stood at $121000.0 in 2010, then sank by 72.73% to $33000.0 in 2011, then slumped by 51.52% to $16000.0 in 2012, then tumbled by 81.25% to $3000.0 in 2013.
• Per Business Quant, the three latest ORKA Current Deferred Revenue figures stand at $3000.0 (Q2 2013), $8000.0 (Q1 2013), and $16000.0 (Q4 2012).